SG11201911598WA - Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis - Google Patents

Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis

Info

Publication number
SG11201911598WA
SG11201911598WA SG11201911598WA SG11201911598WA SG11201911598WA SG 11201911598W A SG11201911598W A SG 11201911598WA SG 11201911598W A SG11201911598W A SG 11201911598WA SG 11201911598W A SG11201911598W A SG 11201911598WA SG 11201911598W A SG11201911598W A SG 11201911598WA
Authority
SG
Singapore
Prior art keywords
endometriosis
gonadotropin
treatment
releasing hormone
dosing regimens
Prior art date
Application number
SG11201911598WA
Inventor
Ernest Loumaye
Jean-Pierre Gotteland
Original Assignee
ObsEva SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ObsEva SA filed Critical ObsEva SA
Publication of SG11201911598WA publication Critical patent/SG11201911598WA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
SG11201911598WA 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis SG11201911598WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762515268P 2017-06-05 2017-06-05
PCT/EP2018/064768 WO2018224498A1 (en) 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis

Publications (1)

Publication Number Publication Date
SG11201911598WA true SG11201911598WA (en) 2020-01-30

Family

ID=62620835

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201911598WA SG11201911598WA (en) 2017-06-05 2018-06-05 Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis

Country Status (11)

Country Link
EP (1) EP3634418A1 (en)
JP (2) JP7348171B2 (en)
KR (1) KR20200027481A (en)
CN (1) CN110996956A (en)
AU (2) AU2018280742B2 (en)
CA (1) CA3066190A1 (en)
EA (1) EA201992612A1 (en)
MA (1) MA49256A (en)
MX (1) MX2019014483A (en)
SG (1) SG11201911598WA (en)
WO (1) WO2018224498A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019014482A (en) 2017-06-05 2020-08-17 ObsEva SA Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood loss.
CA3148939A1 (en) * 2019-08-08 2021-02-11 ObsEva S.A. Compositions and methods for the treatment of estrogen-dependent disorders
CN113384581B (en) * 2020-03-12 2023-11-14 成都倍特药业股份有限公司 Pharmaceutical composition comprising gonadotrophin releasing hormone antagonist
EP4243829A1 (en) * 2020-11-11 2023-09-20 Myovant Sciences GmbH Methods of administering relugolix
CN115232144B (en) * 2021-04-22 2024-04-02 长春金赛药业有限责任公司 Nitrogen-containing condensed ring derivative, pharmaceutical composition, and preparation method and application thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342760A (en) 1992-06-10 1994-08-30 Abbott Laboratories Determination of estradiol by competitive immunoassay
US5663054A (en) 1995-03-03 1997-09-02 Abbott Laboratories Determination of steroids by competitive immunoassay
PL360294A1 (en) 2000-07-05 2004-09-06 Yamanouchi Pharmaceutical Co.Ltd. Propane-1,3-dione derivatives
US7300935B2 (en) 2003-01-29 2007-11-27 Takeda Pharmaceutical Company Thienopyrimidine compounds and use thereof
BRPI0412314B8 (en) 2003-07-07 2021-05-25 Neurocrine Biosciences Inc compound 3-[2(r)-{hydroxycarbonylpropyl-amino}-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl -pyrimidine-2,4(1h,3h)-dione, pharmaceutical composition comprising said compound and its use for the treatment of a condition related to sex hormone
CA2603185C (en) 2005-03-31 2011-07-26 Astellas Pharma Inc. Propane-1,3-dione derivative or salt thereof
ES2398917T7 (en) 2005-10-19 2022-10-26 Kissei Pharmaceutical Condensed heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
WO2009062087A1 (en) 2007-11-07 2009-05-14 Neurocrine Biosciences, Inc. Processes for the preparation of uracil derivatives
SG183243A1 (en) 2010-02-10 2012-09-27 Kissei Pharmaceutical Salt of fused heterocyclic derivative and crystal thereof
SG11201403749VA (en) 2012-01-16 2014-07-30 Bayer Ip Gmbh Spiroindoline derivatives as gonadotropin- releasing hormone receptor antagonists
WO2013126517A1 (en) 2012-02-21 2013-08-29 Northwestern University Anti-mullerian hormone detection in whole blood
CA2883126A1 (en) 2012-09-07 2014-03-13 Astellas Pharma Inc. Method for producing sulfonyl amidine compound
WO2014042176A1 (en) 2012-09-14 2014-03-20 キッセイ薬品工業株式会社 Method for producing fused-heterocyclic derivative, and production intermediate thereof
LT2900675T (en) 2012-09-28 2019-05-27 Takeda Pharmaceutical Company Limited Production method of thienopyrimidine derivative
US10881659B2 (en) 2013-03-15 2021-01-05 Abbvie Inc. Methods of treating heavy menstrual bleeding
AR095785A1 (en) 2013-04-09 2015-11-11 Bayer Pharma AG DERIVATIVES OF SPIROINDOLINE AND PHARMACEUTICAL COMPOSITIONS OF THE SAME
CA3002791A1 (en) 2015-09-01 2017-03-09 Abbvie Inc. Methods of administering elagolix
EP3498280B1 (en) * 2016-08-08 2024-04-03 Kissei Pharmaceutical Co., Ltd. Administration and dosage of therapeutic agent for endometriosis

Also Published As

Publication number Publication date
CN110996956A (en) 2020-04-10
AU2024201701A1 (en) 2024-04-04
JP7348171B2 (en) 2023-09-20
AU2018280742A1 (en) 2020-01-30
EA201992612A1 (en) 2020-05-20
EP3634418A1 (en) 2020-04-15
JP2023113715A (en) 2023-08-16
KR20200027481A (en) 2020-03-12
MA49256A (en) 2021-05-26
MX2019014483A (en) 2020-08-17
AU2018280742B2 (en) 2023-12-21
JP2020522571A (en) 2020-07-30
WO2018224498A1 (en) 2018-12-13
CA3066190A1 (en) 2018-12-13
US20200138819A1 (en) 2020-05-07

Similar Documents

Publication Publication Date Title
IL272069A (en) Dosage regimens of anti-lag-3 antibodies and uses thereof
SG11201911598WA (en) Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosis
IL271222A (en) Dosage regimens for anti-tim-3 antibodies and uses thereof
HUE055109T2 (en) Dosing regimens for anti-tf-antibody drug-conjugates
GB201713653D0 (en) Dosage regimen
ZA201900777B (en) Usage and dosage of therapeutic agents for endometriosis
IL253247B (en) Dosage regimen for madcam antagonists
HK1259307A1 (en) Dosing regimens
IL272864A (en) Il-33 antagonist-containing therapeutic agent for endometriosis
GB201521217D0 (en) Dosage regimens
IL275238A (en) Liquid composition comprising vegf antagonist
IL273419A (en) Dosing regimen of siponimod
IL280515A (en) Dosing regimens for elagolix
IL273382A (en) Dosing regimen of siponimod
IL264139A (en) Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
IL264243B (en) Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
SG10201912141YA (en) Novel dosing regimens of celgosivir for the prevention of dengue
IL252903A0 (en) Cgrp antagonist peptides
GB201614179D0 (en) Dosage regimen for the treatment of endometriosis
GB201720541D0 (en) Dosage regime
GB201720543D0 (en) Dosage regime
GB201720542D0 (en) Dosage regime
ZA201704249B (en) Cgrp antagonist peptides
GB201710493D0 (en) Dosage regime
GB201710496D0 (en) Dosage regime